Participant consumed grapefruit or grapefruit products and solutions within 3 times prior to the 1st dose of study drug. - Participant eaten grapefruit or grapefruit goods within 3 times prior to the primary dose of study drug. In Section C, individuals will receive ABBV-744 and oral navitoclax. In Phase D, https://clinical-effectiveness-of89124.p2blogs.com/31184080/the-2-minute-rule-for-is-abbv-744-effective-for-hematologic-cancers